MyFinsight
Home
Blog
About
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,360K
Free Cash flow
-$106,630K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the sale of conver...
Maturities of marketable securit...
Proceeds from the issuance of co...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepayment of long-term debt
Payments of issuance costs assoc...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-127,119
117,345
-34,599
-187,647
Share-based compensation expense
16,984
-18,924
11,250
21,064
Non-cash interest expense
2,538
2,036
308
-
Depreciation and amortization
117
-219
110
230
Non-cash interest expense and amortization of debt issuance costs
-
-
-
206
Accretion and amortization of available-for-sale securities
1,451
-3,148
1,133
3,872
Non-cash lease expense
2
-
-13
-17
Deferred revenue - related party
-
-
-
-144
Net loss on disposal of equipment
-
-
0
-
Change in fair value of derivative liability
-1,190
7,530
-
-
Unbilled revenue
-
-
70,000
0
Other non-cash items
-
-169
-
-
Loss on extinguishment of debt
-4,449
-
-
-
Prepaid expenses and other assets
2,402
11,183
-3,370
-5,479
Accounts payable
-5,204
-3,312
1,546
6,396
Accrued and other liabilities
6,113
-18,577
4,612
-9,721
Other liabilities
-342
-
-
-
Net cash used in operating activities
-105,324
132,983
-84,611
-168,026
Purchases of marketable securities
378,655
-49,764
14,086
126,998
Maturities of marketable securities
148,804
-274,592
140,290
302,906
Purchase of property and equipment
1,306
-232
127
128
Net cash provided by (used in) investing activities
-231,157
-224,596
126,077
175,780
Proceeds from the sale of convertible notes
250,000
-
-
-
Proceeds from the issuance of common stock-September2022ATMAgreement
-
-
-
4,944
Proceeds from sale of common stock in public offering
-
-
0
-
Proceeds from the issuance of common stock in offerings
143,750
-
-
-
Proceeds from the issuance of common stock-January2024Public Offering
-
-
-
0
Proceeds from sale of common stock in at-the-market offerings
0
-14,904
14,904
-
Payments of issuance costs associated with sale of common stock-Common Stock
-
-
209
207
Payments of issuance costs associated with the sale of common stock
8,270
0
-
-
Proceeds from the issuance of series b preferred stock, pursuant to september 2024 public offering
-
-
0
-
Payments of issuance costs associated with the sale of convertible notes
7,506
-
-
-
Payments of issuance costs associated with sale of common stock-Preferred Stock
-
-
0
-
Prepayment of long-term debt
54,700
-
-
-
Proceeds from the exercise of warrants
0
-1,618
0
1,618
Proceeds from issuance of common stock upon exercises of stock options
577
2,750
547
3,060
Proceeds from issuance of common stock under employee stock purchase plan
1,270
-1,120
559
561
Net cash provided by financing activities
325,121
-14,476
10,857
9,976
Net increase (decrease) in cash and cash equivalents
-11,360
-106,089
52,323
17,730
Cash and cash equivalents at beginning of period
169,647
169,647
99,594
-
Cash and cash equivalents at end of period
164,986
176,346
169,647
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the sale of
convertible notes
$250,000K
Proceeds from the
issuance of common stock...
$143,750K
Proceeds from issuance of
common stock under...
$1,270K
(126.38%↑ Y/Y)
Proceeds from issuance of
common stock upon...
$577K
(-81.14%↓ Y/Y)
Net cash provided by
financing activities
$325,121K
(3159.03%↑ Y/Y)
Canceled cashflow
$70,476K
Net increase
(decrease) in cash and cash...
-$11,360K
(-164.07%↓ Y/Y)
Canceled cashflow
$325,121K
Maturities of marketable
securities
$148,804K
(-50.87%↓ Y/Y)
Share-based compensation
expense
$16,984K
(-19.37%↓ Y/Y)
Accrued and other
liabilities
$6,113K
(162.88%↑ Y/Y)
Loss on
extinguishment of debt
-$4,449K
Non-cash interest
expense
$2,538K
Change in fair value of
derivative liability
-$1,190K
Depreciation and
amortization
$117K
(-49.13%↓ Y/Y)
Non-cash lease expense
$2K
(111.76%↑ Y/Y)
Prepayment of long-term
debt
$54,700K
Payments of issuance
costs associated with...
$8,270K
Payments of issuance
costs associated with...
$7,506K
Net cash provided by
(used in) investing...
-$231,157K
(-231.50%↓ Y/Y)
Canceled cashflow
$148,804K
Net cash used in
operating activities
-$105,324K
(37.32%↑ Y/Y)
Canceled cashflow
$31,393K
Purchases of marketable
securities
$378,655K
(198.16%↑ Y/Y)
Purchase of property and
equipment
$1,306K
(920.31%↑ Y/Y)
Net loss
-$127,119K
(32.26%↑ Y/Y)
Accounts payable
-$5,204K
(-181.36%↓ Y/Y)
Prepaid expenses and
other assets
$2,402K
(143.84%↑ Y/Y)
Accretion and
amortization of...
$1,451K
(-62.53%↓ Y/Y)
Other liabilities
-$342K
Buy us a coffee